Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection

AIDS

Volumn 18, Issue 14, 2004, Pages 1885-1893

  Van Asten, Liselotte ^a   Danisman, Figen ^a   Otto, Sigrid A ^b   Borghans, José A M ^b   Hazenberg, Mette D ^b   Coutinho, Roel A ^a,c   Prins, Maria ^a   Miedema, Frank ^b,c  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CD4 T cell decline; HIV; HIV disease progression; Injecting drug users; Pre seroconversion immune status; TREC

Indexed keywords

CD4 ANTIGEN; KI 67 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRYOPRESERVATION; DRUG ABUSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; T LYMPHOCYTE;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; KI-67 ANTIGEN; MALE; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; SUBSTANCE-RELATED DISORDERS; T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE;

EID: 4744361687     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409240-00004     Document Type: Article

References (31)

1. Weissman D, Barker TD, Fauci AS. The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996, 183:687-692.
2. Quinn TC, Piot P, McCormick JB, Feinsod FM, Taelman H, Kapita B, et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 1987, 257:2617-2621.
3. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17:1881-1888.
4. Ostrow DG, Altman NL. Sexually transmitted diseases and homosexuality. Sex Transm Dis 1983, 10:208-215.
5. William DC. Hepatitis and other sexually transmitted diseases in gay men and in lesbians. Sex Transm Dis 1981, 8:330-332.
6. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997, 11:621-631.
7. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002, 16:597-603.
8. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000, 355:1131-1137.
9. Donahoe RM, Adler MW. Substance abuse and the immune system. Drug Alcohol Depend 2001, 62:109-110.
10. McLachlan C, Crofts N, Wodak A, Crowe S. The effects of methadone on immune function among injecting drug users: a review. Addiction 1993, 88:257-263.
11. Contoreggi C, Rexroad VE, Lange WR. Current management of infectious complications in the injecting drug user. J Subst Abuse Treat 1998, 15:95-106.
12. Alonzo NC, Bayer BM. Opioids, immunology, and host defenses of intravenous drug abusers. Infect Dis Clin North Am 2002, 16:553-569.
13. Donahoe RM, Falek A, Madden JJ, Nicholson JK, Bokos P, Gallegos K, et al. Effects of cocaine and other drugs of abuse on immune function. In: Drugs of abuse, immunity, and immunodeficiency. Edited by Friedman H. New York: Plenum Press, 1991:143-150.
14. Hazenberg MD, Otto SA, Cohen SJ, Verschuren MC, Borleffs JC, Boucher CA, et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000, 6:1036-1042.
15. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med 2001, 79:631-640.
16. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
17. Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95:249-255.
18. SAS Institute I. SAS/STAT Software: Changes and Enhancements through Release 6.12. Cary, NC: SAS Institute; 1996.
19. Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data. Oxford: Clarendon Press; 1995.
20. Krol A, Flynn C, Vlahov D, Miedema F, Coutinho RA, van Ameijden EJC. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug Alcohol Depend 1999, 54:145-154.
21. Prins M, Robertson JR, Brettle RP, Hernandez-Aguado I, Broers B, Boufassa F, et al. Do gender differences in CD4 cell counts matter? AIDS 1999, 13:2361-2364.
22. Zeger SL, Diggle PJ. Semiparametric models for longitudinal data with application to CD4 cell numbers in HIV seroconverters. Biometrics 1994, 50:689-699.
23. Geskus RB. Methods for estimating the AIDS incubation time distribution when date of seroconversion is censored. Stat Med 2001, 20:795-812.
24. Douek DC, McFarland RD, Keiser PH, Gage EA, Massay JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
25. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000, 181:872-880.
26. Cascade Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003, 34:76-83.
27. Hatzakis A, Touloumi C, Karanicolas R, Karafoulidou A, Mandalaki T, Anastassopoulou C, et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 2000, 355:599-604.
28. Goedert JJ, O'Brien TR, Hatzakis A, Kostrikis LG. T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy. AIDS 2001, 15:2245-2250.
29. Richardson MW, Sverstiuk AE, Gracely EJ, Hendel H, Khalili K, Zagury JF, et al. T-cell receptor excision circles (TREC) and maintenance of long-term non-progression status in HIV-1 infection. AIDS 2003, 17:915-917.
30. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJ, Simmonds P, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988, 1:1185-1188.
31. Landay A, Benning L, Bremer J, Weiser B, Burger H, Nowicki M, et al. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis 2003, 188:209-218.